Clinical Studies for the Treatment of Advanced Solid Tumors

NCT06825494 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine
DRUG: Tislelizumab+Oxaliplatin+Capecitabine
DRUG: LM-108 injection 10mg/kg +penpulimab
DRUG: LM-108 injection 600mg + penpulimab
DRUG: enpulimab+ Oxaliplatin+Capecitabine

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.